{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1893",
  "slug": "cancer-escape-routes-getting-named",
  "edition": "2026-11-21T12",
  "url": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Four papers this week named the moves tumours use to escape treatment, and in two of them the same pathway is the target.",
  "headline": "Cancer's escape routes are getting named, one pathway at a time",
  "dek": "Melanoma cells lose their interferon response and dodge T cells, prostate tumours lean on YAP and TAZ, and TEAD blockers that reach the brain extend survival in glioblastoma models.",
  "published_at": "2026-11-21T12:46:31Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 4 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 4,
  "publishers": [
    "biorxiv-cancer-immunology-translation",
    "medrxiv-oncology-hematology"
  ],
  "sources": [
    "biorxiv-cancer-immunology-translation",
    "medrxiv-oncology-hematology"
  ],
  "distinct_source_count": 2,
  "key_facts": [
    {
      "text": "In a preprint, AHR deficiency in melanoma cells leads to delayed resistance to CD8 adoptive T-cell therapy, with progressive loss of interferon gamma responsiveness and MHC expression under chronic stimulation.",
      "cites": [
        {
          "claim_ids": [
            "1795232132203725293",
            "1795232132205725294"
          ],
          "manifest_id": "1795231886473723962"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, decitabine treatment partially restores MHC expression in AHR-deficient melanoma cells, and CD4 cell therapy effectively eradicates AHR-deficient melanomas.",
      "cites": [
        {
          "claim_ids": [
            "1795232132206725295",
            "1795232132207725296"
          ],
          "manifest_id": "1795231886473723962"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint on triple-negative breast cancer, baseline TNF-alpha/NF-kappaB signalling in cytotoxic T/NK and B cells is associated with not reaching a complete response, while a higher proportion of CX3CR1-expressing CD4 cells predicts a complete response with an AUC of 0.949 and a higher switched-memory B-cell CD38 balance predicts it with an AUC of 0.825.",
      "cites": [
        {
          "claim_ids": [
            "1795214707773626828",
            "1795214707774626829",
            "1795214707775626830"
          ],
          "manifest_id": "1795214251708626034"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In preprints, enzalutamide-resistant prostate cancer cells show activation of the YAP-1/TAZ-TEAD complex, and the TEAD inhibitor VT104 reaches the brain with a brain-to-plasma ratio above 150% and extends overall survival in recurrent glioblastoma models when combined with radiotherapy and temozolomide.",
      "cites": [
        {
          "claim_ids": [
            "1795212593353614798"
          ],
          "manifest_id": "1795212277219611307"
        },
        {
          "claim_ids": [
            "1795192497760472699",
            "1795192497761472700"
          ],
          "manifest_id": "1795192148771468838"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "Melanoma learns to hide",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1795232132203725293",
                "1795232132205725294"
              ],
              "manifest_id": "1795231886473723962"
            }
          ],
          "markdown": "In a preprint on melanoma, researchers found that the aryl hydrocarbon receptor, AHR, is what keeps tumour cells responsive to interferon gamma, the signal that helps T cells recognise them. When melanoma cells lose AHR, they progressively lose interferon gamma responsiveness and MHC expression under chronic stimulation, which is how a tumour stops being visible to the immune system, and the result is delayed resistance to CD8 adoptive T-cell therapy."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1795232132206725295",
                "1795232132207725296"
              ],
              "manifest_id": "1795231886473723962"
            }
          ],
          "markdown": "The resistance is not permanent, at least in the experiments. Decitabine treatment partially restores MHC expression in AHR-deficient cells, which points to epigenetic regulation of the resistance, and CD4 cell therapy effectively eradicates AHR-deficient melanomas. The paper's message is that the escape has a mechanism, and a mechanism can be worked around."
        }
      ]
    },
    {
      "heading": "What predicts a full response",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1795214707773626828",
                "1795214707774626829",
                "1795214707775626830"
              ],
              "manifest_id": "1795214251708626034"
            }
          ],
          "markdown": "A preprint on early triple-negative breast cancer followed the immune system through treatment, measuring circulating immune cells in patients receiving pembrolizumab. Baseline TNF-alpha/NF-kappaB signalling in cytotoxic T/NK and B cells was associated with not reaching a pathological complete response, the outcome where no tumour remains by surgery. Two other signals pointed the other way: a higher proportion of CX3CR1-expressing cells within the CD4 memory/activation-like compartment was associated with a complete response, with an AUC of 0.949, and a higher pre-surgery switched-memory B-cell CD38 balance was also higher in patients who reached a complete response, with an AUC of 0.825."
        }
      ]
    },
    {
      "heading": "The same pathway, twice",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1795212593353614798",
                "1795212593356614799",
                "1795212593357614800"
              ],
              "manifest_id": "1795212277219611307"
            }
          ],
          "markdown": "In prostate cancer, the escape route has a name: YAP1/TAZ-TEAD. A preprint finds that enzalutamide-resistant prostate cancer cells show marked activation and nuclear enrichment of the YAP-1/TAZ-TEAD complex, and that increased YAP-1/WWTR1 (Taz) expression is a negative predictor of therapeutic response in patients. Disrupting the YAP-1/TAZ-TEAD interface with CA3 inhibits migration, invasion and colony formation in both AR-dependent and AR-independent prostate cancer cell lines, which makes the axis a target rather than just a marker."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1795192497758472697",
                "1795192497760472699",
                "1795192497761472700",
                "1795192497762472701"
              ],
              "manifest_id": "1795192148771468838"
            }
          ],
          "markdown": "The same axis shows up in the brain. A preprint on recurrent glioblastoma tested TEAD palmitoylation inhibitors VT103 and VT104, which inhibit tumour proliferation and migration in vitro while downregulating TEAD-target expression. VT104 reaches the brain, achieving a brain-to-plasma ratio above 150% in PDX mice, and combined with radiotherapy and temozolomide it significantly extends overall survival in recurrent glioblastoma models. The drug also potentiates temozolomide-dependent genotoxic stress and works with radiotherapy and temozolomide to abolish TEAD activity."
        }
      ]
    },
    {
      "heading": "Why naming the move matters",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1795232132203725293"
              ],
              "manifest_id": "1795231886473723962"
            }
          ],
          "markdown": "The pattern across the four papers is the same: resistance is not a mystery, it is a mechanism, and mechanisms have addresses. AHR loss, YAP and TAZ activation, the immune signals that predict a complete response, each one is a place to aim the next experiment. None of these is a treatment yet. All four are preprints, and the glioblastoma and prostate results come from models and cell lines, not patients. But a field that can name the escape route is a field that can design the next trial around it."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1795214707774626829",
                "1795214707775626830"
              ],
              "manifest_id": "1795214251708626034"
            }
          ],
          "markdown": "The breast cancer paper's two predictors are worth a second look. A CX3CR1 signal with an AUC of 0.949 is a strong predictor by the standards of this kind of work, and the B-cell signal at 0.825 is weaker but points at a different part of the immune system, which is why the paper reports both rather than picking a winner. A strong signal and a weaker one, from different cell types, is more useful than either alone: it suggests the response is written across the immune system, not in a single cell."
        }
      ]
    }
  ],
  "unresolved": [
    "Whether the AHR mechanism operates the same way in patients as in the experiments",
    "Whether the triple-negative breast cancer immune signals predict response in larger cohorts",
    "Whether TEAD inhibitors are safe enough for human trials",
    "Whether targeting YAP/TAZ-TEAD works outside the models tested"
  ],
  "decision_card": {
    "not_for": [
      "Patients looking for treatment advice",
      "Anyone needing peer-reviewed results rather than preprints"
    ],
    "useful_for": [
      "Oncologists and researchers tracking treatment resistance",
      "Drug developers working on immunotherapy combinations"
    ],
    "compare_against": [
      "Existing immunotherapy combinations for melanoma and breast cancer",
      "Standard care for recurrent glioblastoma"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-21T12-batch-other"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1795231886473723962",
    "1795214251708626034",
    "1795212277219611307",
    "1795192148771468838"
  ],
  "manifests": [
    {
      "title": "Tumor cell-intrinsic AHR sustains IFNγ responsiveness and durable CD8 T-cell-mediated melanoma control",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.19.767927v1.full",
      "manifest_id": "1795231886473723962",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-20"
    },
    {
      "title": "Circulating Immune Dynamics During Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.19.26368490v1.full",
      "manifest_id": "1795214251708626034",
      "source_name": "medrxiv-oncology-hematology",
      "published_date": "2026-11-20"
    },
    {
      "title": "Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.19.767854v1.full",
      "manifest_id": "1795212277219611307",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-20"
    },
    {
      "title": "TEAD Palmitoylation Inhibitors are Brain Penetrant and Enhance Survival in Preclinical Models of Recurrent Glioblastoma in Combination with Standard-of-Care Therapy",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.18.767633v1.full",
      "manifest_id": "1795192148771468838",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-20"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1795231886473723962",
      "1795214251708626034",
      "1795212277219611307",
      "1795192148771468838"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. Existing 72 Hour Agent Demo keys keep their issued limits. New keys require email OTP verification. An existing demo key lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1795231886473723962",
      "all": "for id in 1795231886473723962 1795214251708626034 1795212277219611307 1795192148771468838; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/",
    "json": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-21T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/infection-tests-race-resistance/",
      "headline": "The infection test is catching up. The resistance is not waiting.",
      "slug": "infection-tests-race-resistance"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/blood-tests-split-speed-from-stage/",
      "headline": "One blood draw, two different answers about neurodegeneration",
      "slug": "blood-tests-split-speed-from-stage"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-20/drug-resistance-travels-in-chains/",
      "headline": "Drug resistance does not just appear — it travels, in chains you can now trace",
      "slug": "drug-resistance-travels-in-chains"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-20/cell-level-maps-replace-bulk-averages/",
      "headline": "The average hid the signal. Four studies map disease cell by cell.",
      "slug": "cell-level-maps-replace-bulk-averages"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Claims with a source link",
    "text": "A Manifest holds a Signal of structured claims and a Brief, plus the source it came from. Your agent can check a sentence against it.",
    "cta": {
      "label": "Read the guide",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-21/cancer-escape-routes-getting-named/"
  }
}
